Northwell Well being CEO Michael Dowling mentioned that scientists engaged on a drug trial for famotidine, a typical heartburn treatment, have “an inexpensive confidence” that the drug could make a distinction within the remedy of Covid-19 sufferers.
“It is one in all many trials we’re doing, however we consider within the subsequent two weeks or so we’ll have some potential outcomes to have the ability to inform whether or not it is working or not,” Dowling informed AnotherBillionaire Information on Tuesday. He mentioned it is too early to say definitively whether or not or not it really works, however “our scientists have an inexpensive confidence on this trial that it could make a distinction.”
Dowling mentioned there are roughly 200 sufferers presently enrolled within the trial, which makes use of 9 instances the quantity of famotidine that somebody would often take to deal with heartburn, as first reported by Science Journal. Famotidine is a typical ingredient present in Pepcid, a heartburn treatment.
The research, which is underway on the Feinstein Institutes for Medical Analysis, the analysis arm of New York-based well being system Northwell Well being, was stored below wraps to make sure sufficient provide for the trial.
“It is very tough to get in the mean time, I consider Amazon is offered out,” Dowling mentioned. “As a result of as soon as the phrase will get out that that is one thing that would assist, clearly there was a run on the provision, however we do have sufficient to do the trial and do it efficiently.”
The trial is is one in all six to seven underway on the hospital, Dowling mentioned. Northwell can be finding out whether or not Regeneron’s sarilumab, a drug for arthritis, and Gilead Sciences’s remdesivir might additionally assist deal with coronavirus sufferers. There are presently no confirmed therapeutics or vaccines for Covid-19.
That is breaking information. Please test again for updates.